A posttranslational modification code for CFTR maturation is altered in cystic fibrosis

Area of Science:

• Molecular Biology
• Cell Biology
• Genetics

Background:

• Protein misfolding disorders, including cystic fibrosis (CF), arise from disrupted endoplasmic reticulum (ER) and secretory pathway maturation.
• Mutations in the CFTR ion channel impair folding and plasma membrane localization, causing CF, a multi-organ disease primarily affecting the lungs.
• The regulatory insertion (RI) element of CFTR plays a critical role in its maturation process.

Purpose of the Study:

• To investigate the role of posttranslational modifications (PTMs), specifically phosphorylation and methylation, in CFTR maturation.
• To determine if PTM patterns can distinguish correctly folded from misfolded CFTR.
• To explore the potential of PTM manipulation for therapeutic intervention in CF.

Main Methods:

• Analysis of PTMs in wild-type and mutant CFTR, including ΔF508 and N1303K.
• Manipulation of PTMs and observation of CFTR maturation and degradation.
• Cell culture at reduced temperatures (28°C) with kinase CK2α to restore PTM patterns and function.
• Correlation of PTM patterns with treatment efficacy and clinical CF patient data.

Main Results:

• CFTR maturation is critically dependent on the interplay between phosphorylation and methylation within its RI element.
• Altering these PTMs can lead to wild-type CFTR degradation, while mutations like ΔF508 and N1303K induce aberrant PTMs.
• Restoring a wild-type PTM pattern and CFTR function in ΔF508 mutants was achieved at 28°C in the presence of CK2α.
• The identified PTM code accurately predicts treatment efficacy and is linked to clinical CF phenotypes through mutations at modification sites.

Conclusions:

• A specific quantitative and qualitative PTM code governs CFTR maturation, differentiating functional from misfolded protein.
• This PTM code is disrupted in CF and its restoration is linked to therapeutic benefit.
• Findings provide a basis for understanding CFTR folding defects and developing targeted therapies.